Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead.
SHOWNOTES:
• Read the full report "The weight is over: How GLP-1 treatments are reshaping ... Show More
Today
Investing in a fragmented world
US equities have consistently outperformed global peers – that’s why they’re at the core of investment portfolios worldwide. But past performance is becoming less bankable, especially when policy risk, concentration and valuation premia are taken into account. In this episode, we ... Show More
6m 17s
Dec 4
High hopes, heavy footprint: Aviation’s quest for climate-neutral skies
Aviation is one of the hardest sectors to decarbonize: Between 1970 and 2023, total carbon dioxide emissions from aviation increased by around 164%, reaching nearly 1 gigatonne, equivalent to about 2.5% of all human-made carbon dioxide emissions. Mitigating these emissions will r ... Show More
5m 30s
Aug 2025
The FDA Boss on the Agency’s MAHA Makeover
Dr. Marty Makary has criticized the Food and Drug Administration for being "captured" by Big Food and Big Pharma. Now, the surgeon and former professor is in charge. In an interview with host Jessica Mendoza, the new FDA head talks about food dyes, AI, vaccines and the big change ... Show More
21m 7s
Jun 2023
101: Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen
The late Steve Jobs of Apple said “I think the biggest innovation of the 21st century will be at the intersection of biology and technology, a new era is beginning”.
If you want see how biotech can change the world of health, whilst potentially being capable of creating extraordi ... Show More
39m 55s
Jul 2025
ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More
14m 39s
Apr 2024
Can WeightWatchers survive the Wegovy era?
<p>WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the ... Show More
17m 23s